Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

By Qing Zhang, Jiacheng Bi, Xiaodong Zheng, Yongyan Chen, Hua Wang, Wenyong Wu, Zhengguang Wang, Qiang Wu, Hui Peng, Haiming Wei and 2 more. Nature Immunology, 2018

940 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/84e746ccbe8050e8ef62ea0672097243e51fb5a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Shuang Qin
2. Ming Yi
3. Linping Xu
4. Kongming Wu
5. Shengnan Yu
6. S. Luo
7. Tong Fu
8. Song-Yang Wu

Citations in the corpus

• Tumor-infiltrating lymphocytes in the immunotherapy era (2020, background): “Moreover, NK cells were proven critical for therapeutic effects with TIGIT blockade, PD1 blockade and combination therapy.(220) Another receptor expressed on ~50% of peripheral NK cells and on a subset of activated CD8 T cells is NKG2A.”
• Natural killer cells in cancer biology and therapy (2020, background): “In addition to already-well-defined PD-1 and PD-L1, NK cells with reduced amounts of T-cell immunoglobulins and ITIM domain (TIGIT) show higher levels of cytokine secretion, degranulation activity and cytotoxicity [217], and blockade of TIGIT could prevent exhaustion in NK cells [20].”
• Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 (2019, background): “Recently, some groups have reported that co-blockade of TIGIT with other checkpoint receptors, such as PD-1 and TIM-3, can exert synergistic effects in regulating antitumor responses [106, 109, 110].”